These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37226901)

  • 1. Buprenorphine Prescribing and Dosing Limits: Evidence and Policy Goals.
    Coyle DT; Stewart S; Bortz C; Manalo J; Ritvo A; Krsak M
    Subst Abus; 2023; 44(1):17-23. PubMed ID: 37226901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.
    Jones KF; O'Reilly Jacob M; Spetz J; Hailer L; Tierney M
    J Nurs Scholarsh; 2023 May; 55(3):655-664. PubMed ID: 36624606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions.
    Pourmand A; Beisenova K; Shukur N; Tebo C; Mortimer N; Mazer-Amirshahi M
    Am J Emerg Med; 2021 Oct; 48():316-322. PubMed ID: 34274576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations and limitations of buprenorphine prescribing for opioid use disorder in the intensive care unit setting: A narrative review.
    Erstad BL; Glenn MJ
    Am J Health Syst Pharm; 2024 Mar; 81(6):171-182. PubMed ID: 37979138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
    Doernberg M; Krawczyk N; Agus D; Fingerhood M
    Subst Abus; 2019; 40(2):148-153. PubMed ID: 31008694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 11. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine initiation to treat opioid use disorder in emergency rooms.
    Jaeger S; Fuehrlein B
    J Neurol Sci; 2020 Apr; 411():116716. PubMed ID: 32097813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder.
    Andraka-Christou B
    Health Aff (Millwood); 2021 Jun; 40(6):920-927. PubMed ID: 34097509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine Microdosing Cross Tapers: A Time for Change.
    Raheemullah A; Benhamou OM; Kuo J; Lembke A
    Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.
    Jaffe JH; O'Keeffe C
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S3-11. PubMed ID: 12738346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder.
    Varisco T; Shen C; Thornton D
    J Subst Abuse Treat; 2020 Oct; 117():108073. PubMed ID: 32811630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine Initiation in the Era of High-potency Synthetic Opioids: A Call for Community-based Participatory Research to Help Learning Health Systems Provide Precision Medicine for Opioid Use Disorder.
    Fiellin DA
    J Addict Med; 2022 Nov-Dec 01; 16(6):e348-e349. PubMed ID: 36166675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
    Speight C; Caiola C; Tyndall DE; Scott ES
    J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.